Gold prices have been volatile, but not disorderly. Movements can largely be explained by familiar forces: real interest rates, the strength of the dollar, expectations around monetary easing, and shifts in risk appetite. There is no evidence of empty vaults, failed settlements, or a breakdown in the mechanics of the gold market. And yet, unease […] The post Gold, Paper Claims and the Lebanese Lesson appeared first on Web-Release.

    Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.